Collaboration aims to advance targeted protein degradation technologies
by |
The Centre for Medicines Discovery at the University of Oxford and BPGbio, an artificial intelligence (AI)-focused biopharmaceutical company, established a five-year research collaboration that aims to advance new technologies for treatments for people with brain diseases like Parkinson’s who have limited options.
Together the partners will validate and use BPGbio’s NAi interrogative biology platform to accelerate biomarker discovery, and the development of therapeutics, by combining patient biology with AI-driven analysis. In particular, BPGbio focuses on developing novel technologies using targeted protein degradation, or the selective breakdown and elimination of harmful disease-causing proteins.
…
Read the full article at Parkinson’s News Today: BPGbio, University of Oxford team up on treatments for Parkinson’s
